Deep learning‐enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis
The established 3D imaging and quantification approach provides a powerful tool for evaluating the therapeutic efficacy of antifibrotic compounds and studying the pathological mechanisms underlying cardiovascular diseases.
Authors
- Casper G. Salinas (ORCID: https://orcid.org/0000-0003-3485-8331)
- Ditte Marie Jensen (ORCID: https://orcid.org/0000-0003-2623-6882)
- Urmas Roostalu (ORCID: https://orcid.org/0000-0002-7849-2055)
- Max Hahn (ORCID: https://orcid.org/0000-0002-0712-8256)
- Louise Thisted (ORCID: https://orcid.org/0000-0002-7783-8122)
- Michael Christensen (ORCID: https://orcid.org/0000-0003-1693-058X)
- Tor Biering‐Sørensen (ORCID: https://orcid.org/0000-0003-4209-2778)
- Geoffrey Teixeira
- Sheyla Barrado‐Ballestero
- Sarah Torp Yttergren
- Marie Biviano Rosenkilde
- Heidi Lindgreen Holmberg
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Novo Nordisk (Denmark) (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
- Gubra (Denmark) (DK)
- CRISPR Therapeutics (Switzerland) (CH)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1111/bph.70217
- Citations
- 1
- Primary Topic
- Cardiac Fibrosis and Remodeling
- Type
- article
- Field-Weighted Citation Impact
- 1.39